Kalvista Pharmaceuticals EBITDA vs. Market Capitalization

KALV Stock  USD 9.32  0.36  4.02%   
Based on Kalvista Pharmaceuticals' profitability indicators, Kalvista Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Kalvista Pharmaceuticals' ability to earn profits and add value for shareholders.
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-134.3 M
Current Value
-127.6 M
Quarterly Volatility
45.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Price To Sales Ratio is likely to drop to 46.33 in 2024. Days Sales Outstanding is likely to drop to 267.64 in 2024. Kalvista Pharmaceuticals reported Income Tax Expense of (8.45 Million) in 2023. Net Interest Income is likely to climb to about 4.1 M in 2024, despite the fact that Operating Income is likely to grow to (24.2 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.091.14
Sufficiently Down
Slightly volatile
For Kalvista Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kalvista Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kalvista Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kalvista Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kalvista Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kalvista Pharmaceuticals. If investors know Kalvista will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kalvista Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.57)
Revenue Per Share
0.214
Quarterly Revenue Growth
0.307
Return On Assets
(0.54)
Return On Equity
(0.91)
The market value of Kalvista Pharmaceuticals is measured differently than its book value, which is the value of Kalvista that is recorded on the company's balance sheet. Investors also form their own opinion of Kalvista Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kalvista Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kalvista Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kalvista Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kalvista Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kalvista Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kalvista Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Kalvista Pharmaceuticals Market Capitalization vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Kalvista Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Kalvista Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Kalvista Pharmaceuticals is rated below average in ebitda category among its peers. It is rated below average in market capitalization category among its peers . Kalvista Pharmaceuticals reported EBITDA of (134.28 Million) in 2023. Comparative valuation analysis is a catch-all technique that is used if you cannot value Kalvista Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Kalvista Market Capitalization vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Kalvista Pharmaceuticals

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(134.28 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

Kalvista Pharmaceuticals

Market Cap

 = 

Shares Outstanding

X

Share Price

 = 
458.93 M
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.

Kalvista Market Capitalization vs Competition

Kalvista Pharmaceuticals is rated below average in market capitalization category among its peers. Market capitalization of Health Care industry is now estimated at about 43.25 Billion. Kalvista Pharmaceuticals claims roughly 458.93 Million in market capitalization contributing just under 2% to equities under Health Care industry.
Capitalization  Workforce  Valuation  Total debt  Revenue

Kalvista Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Kalvista Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kalvista Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Kalvista Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Kalvista Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-3.5 M-628 K
Operating Income-140.4 M-24.2 M
Income Before Tax-135.1 M-24.8 M
Total Other Income Expense Net5.3 M-3.8 M
Net Loss-126.6 M-24.8 M
Net Loss-24.8 M-26.1 M
Net Loss-126.6 M-24.8 M
Interest Income3.9 M1.2 M
Non Operating Income Net Other-2.6 M-2.5 M
Net Interest Income3.9 M4.1 M
Change To Netincome3.4 M3.8 M
Net Loss(3.44)(6.17)
Income Quality 0.70  0.88 
Net Income Per E B T 0.94  1.01 

Kalvista Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Kalvista Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kalvista Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kalvista Pharmaceuticals' important profitability drivers and their relationship over time.

Use Kalvista Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kalvista Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kalvista Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Kalvista Pharmaceuticals Pair Trading

Kalvista Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Kalvista Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kalvista Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kalvista Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kalvista Pharmaceuticals to buy it.
The correlation of Kalvista Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kalvista Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kalvista Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kalvista Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Kalvista Pharmaceuticals position

In addition to having Kalvista Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Mid Cap ETFs Thematic Idea Now

Mid Cap ETFs
Mid Cap ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Mid Cap ETFs theme has 70 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Mid Cap ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.